Cell-mediated immunity in HIV seronegative patients recovered from Cryptococcus neoformans var. gattii meningitis

Journal of Medical and Veterinary Mycology

Volumn 35, Issue 1, 1997, Pages 7-11

  Seaton, R A ^a,b   Naraq, S ^a   Wembri, J P ^a   Warrell, D A ^b  

^a UNIVERSITY OF PAPUA NEW GUINEA   (Papua New Guinea)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cell mediated immunity; Cryptococcal meningitis; Cryptococcus neoformants; var. gattii

Indexed keywords

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MENINGITIS; PROVOCATION TEST; SEX DIFFERENCE;

CRYPTOCOCCUS BACILLISPORUS; FILOBASIDIELLA NEOFORMANS;

EID: 79961215279     PISSN: 02681218     EISSN: None     Source Type: Journal    
DOI: 10.1080/02681219780000801     Document Type: Article

References (19)

1. Kwon-Chung KJ, Bennett JE. 'Cryptococcosis' in Medical Mycology. Philadelphia: Lea and Febiger, 1992: 397-446.
2. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990; 28: 1642-4.
3. Pfeiffer T, Ellis D. Environmental isolation of Cryptococcus neoformans var. gattii from California. J Infect Dis 1991; 163: 929-30.
4. Pfeiffer TJ, Ellis DH. Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis. J Med Vet Mycol 1992; 30: 407-8.
5. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984; 120: 123-30.
6. Seaton RA, Naraqi S, Wembri JP, Warrell DA. Predictors of outcome in Cryptococcus neoformans var. gattii meningitis. Q J Med 1996; 89: 423-8.
7. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20: 611-16.
8. Rozenbaum R, Goncalves AJ. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994; 18: 369-80.
9. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21: 28-34.
10. Seaton RA, Verma N, Naraqi S. Ophthalmic findings in Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg 1996; 90: 7.
11. Graybill JR, Alford RH. Cell-mediated immunity in cryptococcosis. Cell Immunol 1974; 14: 12-21.
12. Seaton RA, Wembri JP, Naraqi S. Immunological aspects of cryptococcal meningitis in Papua New Guinea. Aust N Z J Med 1995; 25: 562.
13. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982; 15: 535-7.
14. Kniker WT, Anderson CT, Roumiantzeff M. The multi-test system: standardized approach to evaluation of delayed hypersensitivity and cell mediated immunity. Ann Allergy 1979; 43: 73-79.
15. Maxwell AP, McCluskey DR. Assessment of cell-mediated immunity in a British population using multiple skin test antigens. Clin Allergy 1986; 16: 365-9.
16. Moesgaard F, Lykkegaard-Nielsen M, Norgaard-Larsen P, Christopherson S, Mosbech H. Cell-mediated immunity assessed by skin testing (Multitest). Allergy 1987; 42: 591-6.
17. Marrie TJ, Durant H. A positive response to any of seven intradermal antigens predicts favorable outcome in patients hospitalized with community acquired pneumonia. Clin Invest Med 1988; 11: 10-15.
18. Schimpff SC. Bennett JE. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol 1975; 55: 430-41.
19. Ellis DH, Pfeiffer TJ. Ecology, life cycle and infectious propagule of Cryptococcus neoformans. Lancet 1990; 336: 923-5.